TVM Capital is a global venture and growth capital firm that aims to finance select biopharmaceutical and medical device companies.
Business Model:
Revenue: $15.2M
Employees: 2-10
Address: Ottostrabe 4
City: Munich
State: bavaria
Zip: 80333
Country: DE
TVM Capital is a global venture and growth capital firm that aims to finance select biopharmaceutical and medical device companies. TVM Capital was founded in 1983 and is based Munich, Bavaria.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
12/1999 | Interactive Silicon | Series B | - |
1/2006 | Cambridge Broadband Networks | Series D | 9M |
12/2010 | Cambridge Broadband Networks | Venture Round | 16.5M |
5/2007 | Netviewer | Venture Round | 12.2M |
12/2009 | Arteris IP | Series D | 9.7M |
10/2004 | Impress Software Solutions | Series B | 7.6M |
1/2004 | BitWave | Series A | 13M |
6/2008 | Vivendy Therapeutics | Series B | 30.5M |
2/2005 | Jerini | Venture Round | 20.2M |
4/2007 | ExtendMedia | Series B | 12M |
1/2009 | Revolt Technology | Series B | 13.1M |
11/2013 | Argos Therapeutics | Series E | 0 |
8/2009 | Ubidyne | Series B | 0 |
4/2012 | Argos Therapeutics | Series D | 0 |
3/2010 | Bluebird Bio | Series B | 35M |
7/2006 | CoreOptics | Venture Round | 0 |
10/2003 | Arrow Therapeutics | Series B | 34.9M |
3/2010 | VPIsystems | Venture Round | 0 |
12/2007 | Vivendy Therapeutics | Series A | 15.4M |
10/2007 | DIREVO Industrial Biotechnology | Series C | 0 |
10/2012 | Definiens | Venture Round | 0 |
2/2005 | Aventeon | Series B | 5M |
3/2004 | TransMolecular | Series C | 0 |
3/2007 | Azea Networks | Series D | 6M |
4/2010 | DIREVO Industrial Biotechnology | Series D | 8.1M |
8/2001 | Interactive Silicon | Series C | 0 |
4/2008 | CoreOptics | Venture Round | 0 |
7/2012 | Bluebird Bio | Series D | 0 |
12/2002 | Arrow Therapeutics | Venture Round | 10.9M |
1/2001 | Morphics Technology | Series C | 0 |
11/2006 | Abionyx Pharma | Series B | 53.5M |
2/2010 | DIREVO Industrial Biotechnology | Venture Round | 8.4M |
8/2005 | Amnis | Series C | 11.3M |
3/2014 | invendo medical | Venture Round | 0 |
3/2006 | Proteon Therapeutics | Series A | 19M |
3/2006 | Helomics | Venture Round | 20M |
5/2010 | Noxxon Pharma | Series D | 40.7M |
12/2008 | ExtendMedia | Venture Round | 10M |
1/2002 | TissueInformatics | Venture Round | 0 |
8/2009 | Rapid Micro Biosystems | Series A | 18.6M |
10/2008 | Silicon Hive | Venture Round | 7M |
4/2007 | Silicon Hive | Series A | 10M |
11/2001 | Helomics | Series B | 17.5M |
9/2005 | Ubidyne | Series A | 15.5M |
11/2007 | Enigma Semiconductor | Series B | 5.6M |
2/2009 | Cambridge Broadband Networks | Venture Round | 7.5M |
3/2005 | Sirtris Pharmaceuticals | Series B | 27M |
4/2006 | Sirtris Pharmaceuticals | Series C | 37M |
4/2014 | Rapid Micro Biosystems | Venture Round | 0 |
8/2008 | SpePharm | Venture Round | 0 |
6/2007 | Arteris IP | Series B | 8.1M |
6/2010 | Helomics | Series D | 33M |
1/2008 | RIEMSER Pharma | Venture Round | - |
4/2003 | VPIsystems | Series E | 7M |
2/2008 | Albireo Pharma | Series A | 40M |
4/2004 | Aventeon | Series A | 4.5M |
12/2005 | Curacyte AG | Series C | 74.8M |
11/2007 | Ascent Therapeutics | Series A | 19M |
5/2008 | Arteris IP | Series C | 7.5M |
8/2008 | BitWave | Series B | 10M |
3/2004 | Enigma Semiconductor | Series B | 12.5M |
11/2009 | Vivoryon Therapeutics | Series B | 0 |
8/2006 | Magen BioSciences | Series A | 15.4M |
1/2012 | Vivoryon Therapeutics | Venture Round | 19.4M |
12/2004 | VPIsystems | Series F | 0 |
9/2000 | TransMolecular | Series B | 0 |
5/2007 | Noxxon Pharma | Series C | 50.2M |
5/2005 | WILEX | Series C | 38.4M |
4/2000 | eCustomers.com | Series B | 18M |
10/2005 | Newron Pharmaceuticals | Series B | 8.4M |
1/2007 | Hymite | Series B | 11.5M |
3/2004 | Hymite | Series B | 11.9M |
4/2011 | F-Star Therapeutics | Venture Round | 0 |
3/2006 | BioXell | Series C | 12.7M |
4/1999 | eCustomers.com | Seed Round | - |
1/2007 | Cambridge Broadband Networks | Series E | 22.5M |
9/2002 | Clearsight Systems | Series A | 9.8M |
7/2010 | Abionyx Pharma | Series C | 0 |
6/2013 | Rapid Micro Biosystems | Series B | 0 |
9/2005 | Impress Software Solutions | Series C | 10M |
10/2013 | F-Star Therapeutics | Series A | 0 |
4/2011 | Bluebird Bio | Series C | 30M |
1/2010 | F-Star Therapeutics | Series A | 11.5M |
8/2010 | Anchor Therapeutics | Series B | 10M |
12/2004 | Sirtris Pharmaceuticals | Series A | 13M |
9/2006 | RenaMed Biologics | Venture Round | 0 |
4/2008 | Concert Pharmaceuticals | Series C | 0 |
5/2009 | Proteon Therapeutics | Series B | 50M |
4/2008 | Transave | Series D | 35M |
7/2006 | Concert Pharmaceuticals | Series A | 10M |
4/2015 | Rapid Micro Biosystems | Series C | 0 |
5/2014 | Proteon Therapeutics | Series D | 0 |
5/2000 | PolyTrax Information Technology | Series B | 0 |
6/2014 | Definiens | Venture Round | 0 |
5/2008 | Winbox Technologies | Series A | 1.6M |
6/2002 | VPIsystems | Series C | 20M |
9/2008 | CommProve | Venture Round | 14M |
3/2005 | VPIsystems | Venture Round | 0 |
9/2007 | Proteon Therapeutics | Series A | 12M |
11/2006 | Concert Pharmaceuticals | Series B | 48.5M |
8/2011 | Proteon Therapeutics | Series C | 15.2M |
4/2015 | Rapid Micro Biosystems | Series C | 0 |
6/2014 | Definiens | Venture Round | 0 |
5/2014 | Proteon Therapeutics | Series D | 0 |
4/2014 | Rapid Micro Biosystems | Venture Round | 0 |
3/2014 | invendo medical | Venture Round | 0 |
11/2013 | Argos Therapeutics | Series E | 0 |
10/2013 | F-Star Therapeutics | Series A | 0 |
6/2013 | Rapid Micro Biosystems | Series B | 0 |
10/2012 | Definiens | Venture Round | 0 |
7/2012 | Bluebird Bio | Series D | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|